

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS

This announcement is made by 3D Medicines Inc. (the “**Company**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) has noted the unusual fluctuations in the price and trading volume of the shares of the Company (the “**Shares**”) on July 19 and July 20, 2023. Having made all such enquiries with respect to the Company as is reasonable in the circumstances, the Board confirms that it is not aware of any reasons for those price or trading volume movements or of any information that needs to be disclosed to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The Board also confirms that the Group’s business operation remains in good condition, and that there is no material adverse change to the business operation and financial position of the Group.

This announcement is made by the order of the Board. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

Shareholders of the Company and public investors are advised to exercise caution in dealing with the Shares.

By Order of the Board

3D Medicines Inc.

Dr. Gong Zhaolong

Chairman of the Board and Executive Director

Hong Kong, July 20, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.